Leiden, The Netherlands, 8 July 2022

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it will present new preclinical data on the pharmacodynamics, toxicokinetics, and safety of VMX-C001, its lead compound, at the 2022 ISTH (International Society on Thrombosis and Haemostasis) Congress in London.

VarmX will deliver an oral presentation on Sunday, 10 July at 15.15-15.30 BST, and will showcase a poster on Tuesday 12 July at 18.30-19.30 BST.

VarmX is developing VMX-C001, a modified recombinant blood factor X, for the treatment of severe bleeding and the prevention of bleeding during surgery in patients taking direct oral factor FXa-inhibiting anticoagulants (DOACs). Last December, the Company announced treatment of the first subjects in its first-in-human study for VMX-C001.

In the oral presentation, VarmX’s Director of Research, Daniël Verhoef will present new preclinical data demonstrating that VMX-C001 displays a favorable pharmacodynamic profile in animal models and is an effective factor Xa inhibitor bypassing agent. The abstract, which was selected by the conference organizers for oral presentation, is available here.

Dr. Daniël Verhoef will also present a poster showcasing new preclinical data on the safety and toxicokinetics of VMX-C001 as an intravenous bypassing agent for factor Xa inhibitors. The abstract is available here.

Pieter Reitsma, Founder and CSO of VarmX, commented: “We are happy and grateful that the ISTH Congress organizers have recognized the impact and importance of the new preclinical data package that details pharmacological and safety aspects of VMX-C001. This work has paved the way to initiation of our first-in-human study of VMX-C001, which is now ongoing, and the resulting transition of VarmX from a preclinical into a clinical company.”